Trevena, Inc. (TRVN)
USD 1.27
(-0.78%)
USD 1.27
(-0.78%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -35.28 Million USD | 37.4% |
| 2022 | -56.37 Million USD | -8.57% |
| 2021 | -51.92 Million USD | -76.11% |
| 2020 | -29.48 Million USD | -10.93% |
| 2019 | -26.58 Million USD | 12.85% |
| 2018 | -30.49 Million USD | 56.67% |
| 2017 | -70.38 Million USD | 31.18% |
| 2016 | -102.28 Million USD | -102.06% |
| 2015 | -50.62 Million USD | -1.34% |
| 2014 | -49.94 Million USD | -113.96% |
| 2013 | -23.34 Million USD | -49.55% |
| 2012 | -15.61 Million USD | 0.89% |
| 2011 | -15.75 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -6.5 Million USD | 34.17% |
| 2024 Q1 | -9.87 Million USD | 2.65% |
| 2023 Q2 | -6.19 Million USD | 38.77% |
| 2023 FY | -35.28 Million USD | 37.4% |
| 2023 Q4 | -10.14 Million USD | -14.95% |
| 2023 Q3 | -8.82 Million USD | -42.46% |
| 2023 Q1 | -10.11 Million USD | -8.26% |
| 2022 Q1 | -16.46 Million USD | -17.29% |
| 2022 FY | -56.37 Million USD | -8.57% |
| 2022 Q4 | -9.34 Million USD | 40.67% |
| 2022 Q3 | -15.75 Million USD | -6.36% |
| 2022 Q2 | -14.81 Million USD | 10.01% |
| 2021 FY | -51.92 Million USD | -76.11% |
| 2021 Q2 | -14.07 Million USD | -41.33% |
| 2021 Q4 | -14.03 Million USD | -1.25% |
| 2021 Q1 | -9.95 Million USD | 17.11% |
| 2021 Q3 | -13.86 Million USD | 1.52% |
| 2020 Q4 | -12.01 Million USD | -122.89% |
| 2020 Q1 | -5.82 Million USD | 10.0% |
| 2020 Q2 | -6.25 Million USD | -7.47% |
| 2020 FY | -29.48 Million USD | -10.93% |
| 2020 Q3 | -5.39 Million USD | 13.87% |
| 2019 Q4 | -6.47 Million USD | 26.1% |
| 2019 Q3 | -8.75 Million USD | -42.57% |
| 2019 Q1 | -5.21 Million USD | 34.42% |
| 2019 Q2 | -6.14 Million USD | -17.78% |
| 2019 FY | -26.58 Million USD | 12.85% |
| 2018 Q1 | -9.69 Million USD | 31.33% |
| 2018 FY | -30.49 Million USD | 56.67% |
| 2018 Q4 | -7.95 Million USD | -86.73% |
| 2018 Q3 | -4.25 Million USD | 50.46% |
| 2018 Q2 | -8.59 Million USD | 11.33% |
| 2017 Q2 | -19.88 Million USD | 5.2% |
| 2017 Q1 | -20.97 Million USD | 41.47% |
| 2017 FY | -70.38 Million USD | 31.18% |
| 2017 Q4 | -14.11 Million USD | 8.42% |
| 2017 Q3 | -15.41 Million USD | 22.49% |
| 2016 Q1 | -17.79 Million USD | -14.85% |
| 2016 Q2 | -19.02 Million USD | -6.91% |
| 2016 FY | -102.28 Million USD | -102.06% |
| 2016 Q4 | -35.83 Million USD | -20.95% |
| 2016 Q3 | -29.62 Million USD | -55.73% |
| 2015 Q3 | -10.55 Million USD | 8.28% |
| 2015 Q1 | -13.06 Million USD | 1.37% |
| 2015 Q2 | -11.5 Million USD | 11.91% |
| 2015 FY | -50.62 Million USD | -1.34% |
| 2015 Q4 | -15.49 Million USD | -46.79% |
| 2014 Q2 | -11.5 Million USD | -19.19% |
| 2014 Q1 | -9.65 Million USD | -14.97% |
| 2014 FY | -49.94 Million USD | -113.96% |
| 2014 Q4 | -13.24 Million USD | 14.78% |
| 2014 Q3 | -15.54 Million USD | -35.08% |
| 2013 Q2 | -4.27 Million USD | -50.68% |
| 2013 Q1 | -2.83 Million USD | 9.64% |
| 2013 Q4 | -8.39 Million USD | -7.09% |
| 2013 FY | -23.34 Million USD | -49.55% |
| 2013 Q3 | -7.84 Million USD | -83.53% |
| 2012 Q4 | -3.13 Million USD | 22.6% |
| 2012 Q3 | -4.05 Million USD | 0.0% |
| 2012 FY | -15.61 Million USD | 0.89% |
| 2011 FY | -15.75 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -7062.982% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -270.75% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -17.654% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 47.444% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -122.736% |
| Better Therapeutics, Inc. | -38.26 Million USD | 7.773% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 16.129% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -194.803% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -4.267% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -2.525% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 67.466% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -1651.872% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -3.782% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 24.841% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -2480.69% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -76.977% |
| Molecular Templates, Inc. | -10.46 Million USD | -237.168% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -151.144% |
| NexImmune, Inc. | -29.19 Million USD | -20.88% |
| Orgenesis Inc. | -53.63 Million USD | 34.208% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 31.204% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -45131.168% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -118.566% |
| Scopus BioPharma Inc. | -11.71 Million USD | -201.224% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 93.003% |
| Statera Biopharma, Inc. | -98.34 Million USD | 64.118% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -411.569% |
| Vaxxinity, Inc. | -58.28 Million USD | 39.456% |
| Vaccinex, Inc. | -22.88 Million USD | -54.197% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -3270.462% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 30.389% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -385.859% |